Humacyte, Inc. (NASDAQ:HUMA) Insider Buys $11,625.00 in Stock

Humacyte, Inc. (NASDAQ:HUMA) insider Shamik J. Parikh acquired 7,500 shares of the company’s stock in a transaction that occurred on Thursday, April 10th. The stock was purchased at an average price of $1.55 per share, for a total transaction of $11,625.00. Following the purchase, the insider now owns 7,500 shares of the company’s stock, valued at $11,625. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Humacyte Stock Up 0.6 %

Humacyte stock opened at $1.55 on Thursday. The business has a 50-day simple moving average of $2.71 and a 200 day simple moving average of $4.10. Humacyte, Inc. has a 52 week low of $1.15 and a 52 week high of $9.97. The stock has a market cap of $240.43 million, a price-to-earnings ratio of -1.16 and a beta of 1.62.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings data on Friday, March 28th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.07. The company had revenue of $7.23 million for the quarter, compared to the consensus estimate of $0.64 million. On average, research analysts anticipate that Humacyte, Inc. will post -1.27 earnings per share for the current year.

Analyst Ratings Changes

HUMA has been the subject of several research reports. D. Boral Capital reiterated a “buy” rating and set a $25.00 price target on shares of Humacyte in a research note on Wednesday, March 26th. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Humacyte in a research note on Wednesday, March 12th. Finally, Benchmark reissued a “buy” rating on shares of Humacyte in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $13.71.

Hedge Funds Weigh In On Humacyte

Institutional investors and hedge funds have recently bought and sold shares of the stock. Woodline Partners LP increased its stake in shares of Humacyte by 235.7% in the fourth quarter. Woodline Partners LP now owns 2,848,802 shares of the company’s stock worth $14,386,000 after buying an additional 2,000,268 shares during the period. State Street Corp boosted its position in Humacyte by 66.1% during the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company’s stock valued at $25,917,000 after buying an additional 1,895,529 shares during the period. CenterBook Partners LP bought a new stake in Humacyte in the 4th quarter worth $6,463,000. Brevan Howard Capital Management LP increased its position in shares of Humacyte by 2,795.1% in the fourth quarter. Brevan Howard Capital Management LP now owns 876,340 shares of the company’s stock valued at $4,426,000 after acquiring an additional 846,070 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Humacyte by 10.8% during the fourth quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company’s stock valued at $28,294,000 after acquiring an additional 543,995 shares during the last quarter. 44.71% of the stock is currently owned by institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.